U.S. market Closed. Opens in 17 hours 11 minutes

BTAI | BioXcel Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue1.38M375.00KN/AN/AN/AN/AN/AN/A
Cost of Revenue1.58M20.00K297.00K188.00K156.00KN/AN/AN/A
Gross Profit-198.00K355.00K-297.00K-188.00K-156.00KN/AN/AN/A
Operating Expenses166.13M160.00M106.94M82.30M33.60M19.96M4.54MN/A
Selling, General & Admin83.20M68.76M54.23M24.30M7.80M5.40M1.85M721.00K
Research & Development82.93M91.24M52.71M57.99M25.80M14.56M2.69M1.40M
Other Operating Expenses394.00K-427.00KN/AN/AN/AN/AN/AN/A
Operating Income-166.33M-159.65M-106.94M-82.30M-33.60M-19.96M-4.54M-2.12M
Other Expenses / Income-12.72M-6.11M4.00K128.00K633.00K692.00K-2.00KN/A
Before Tax Income-179.05M-165.76M-106.93M-82.17M-32.97M-19.27M-4.54M-2.12M
Income Tax Expenses150.10K6.09M-301.00K-161.00K-633.00K692.00KN/AN/A
Net Income-179.05M-171.85M-106.63M-82.01M-32.34M-19.27M-4.54M-2.12M
Interest Expenses13.31M8.21M40.00K27.00KN/AN/A2.00KN/A
Basic Shares Outstanding29.13M28.02M26.37M21.68M16.29M14.57M15.65M15.65M
Diluted Shares Outstanding29.13M28.02M26.37M21.68M16.29M14.57M15.65M15.65M
EBITDA-166.01M-157.54M-106.94M-82.30M-34.08M-20.64M-4.54M-2.12M
EBITDA Margin-12,030.07%-42,011.73%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-165.59M-157.54M-106.89M-82.14M-32.97M-18.58M-4.54M-2.12M
EBIT Margin-11,999.20%-42,011.73%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙